d2c7
mAbexperimentalADC
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2015 (NCT02303678)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
EGFR inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- Pseudomonas exotoxin A
Oral
No
Parenteral
No
Topical
No
Also known as
- d2c7
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06455605 | Phase 1 | Nov 1, 2024 | Duke University, Rockefeller University |
| NCT05734560 | Phase 1/Phase 2 (Phase 2) | Sep 6, 2023 | Duke University, Rockefeller University |
| NCT04547777 | Phase 1 | Dec 31, 2020 | Duke University, Rockefeller University |
| NCT04160494 | Phase 1 | Dec 31, 2019 | Duke University, Genentech, Istari Oncology, Inc., National Cancer Institute (NCI) |
| NCT02303678 | Phase 1 | Feb 1, 2015 | Duke University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Duke University | Academic/Hospital | 5 | 5 | 2 | 2015 |
| Rockefeller University | Academic/Hospital | 3 | 0 | 2 | 2020 |
| Genentech | For profit | 1 | 0 | 1 | 2019 |
| Istari Oncology, Inc. | For profit | 1 | 0 | 1 | 2019 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2019 |
5 organizations
Page 1 / 1